Antibody

214개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved214 programs
AntibodyCurated CoreFDARocheApproved

trastuzumab (Herceptin, Ogivri, Herzuma)

HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2

#HER2#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1100Status Approved
AntibodyCurated CoreFDARocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
AntibodyCurated CoreFDABeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyCurated CoreFDAJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyCurated CoreFDAAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
AntibodyCurated CoreBristol Myers SquibbPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 470Status Active
AntibodyCurated CorestaleAstraZenecaPhase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 195Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 185Status Recruiting
AntibodyCurated CorestaleRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 153Status Recruiting
AntibodyLimited DatastaleInnoventPhase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 152Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 141Status Active
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 127Status Recruiting
AntibodyLimited DatastaleAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 127Status Recruiting
AntibodyCurated CorestaleEli Lilly and CompanyPhase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 117Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 94Status Active
AntibodyLimited DatastaleAkesoPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 85Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Venous Thrombosis · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 82Status Recruiting
AntibodyCurated CorestaleBelfast Health and Social Care …Approved

Golimumab (Golimumab)

Psoriatic Arthritis; Psoriasis · Chronic Nonbacterial Osteomyelitis

#ChronicNonbacterialOsteomyelitis#Antibody#Approved#BioJungboMoa-pick#Popular+5
Trials 80Status Discontinued
AntibodyCurated CorestaleAkesoPhase 2

Ivonescimab (Ivonescimab)

Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma · HER2

#HER2#Antibody#Phase2#BioJungboMoa-pick#Popular+5
Trials 78Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 65Status Active

1 / 11 pages

← PreviousNext →